Matrix Japan invests in or co-founds companies that contribute meaningfully to Japan's economy and society — undertaken only where the firm has conviction in both founders and mission.
Japanese universities, pharmaceutical companies and biotechs hold some of the best research in the world, but do not always have the balance-sheet strength or the human resources to develop every asset to commercialisation.
Valuable assets — often deprioritised for strategic, portfolio-balance or pipeline-sequencing reasons — sit idle inside originating institutions despite genuine clinical and commercial potential.
Co-founder of J-Biosciences K.K., with Jerrod Stelli serving as Representative Director（代表取締役）. The firm has provided approximately 50% of seed capital to date and continues to lead strategic direction and capital formation.
— In-license or acquire deprioritised assets from Japanese originators
— Develop assets lean and globally through outsourced clinical work
— Provide flexible structures, including reacquisition rights for the originator
— Focus on assets with clear clinical and commercial potential that need a dedicated home
Detailed asset profile, capital plan and scientific leadership are available upon request, subject to NDA.
Request materials